Skip to main content

Table 2 Anthropological and clinical characteristics of 12 outpatients with COPD, treated with ESAs and intravenous iron for anemia

From: Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron

Characteristics

Number (%)

Age (years)

74.0 [66.5–79.5]

Male

6 (50%)

FEV1 (% predicted)

46.5% [40–55]

FEV1/FVC (% predicted)

65.5 [49–68]

Basal Oxygan saturation (%)

94.5 [92–96]

CHF

9 (75%)

Diabetes Mellitus

6 (50%)

Hypertension

11 (92%)

CKD

12 (100%)

Dyslipidemia

8 (67%)

Obesity

3 (25%)

Smoking

8 (67%)

Inhaled Bronchodilators

12 (100%)

ACE-I

7 (59%)

ARBs

3 (25%)

Beta-blockers

10 (84%)

Statins

8 (67%)

  1. Abbreviations: ACE-I, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor ii blockers; CHF, congestive heart failure, CKD, chronic kidney disease; ESAs, erythropoiesis stimulating agents; FEV1, one second Forced Expiratory Volume; FVC, Forced Vital Capacity.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us